Qiagen N.V.

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 10:30:02 03/07/2024 pm IST			5-day change	1st Jan Change
40.58 ^USD	-0.29%		-0.37%	-9.37%

27/06	Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50	MT
21/06	Qiagen Seeks M&A	CI

Tranche Update on Qiagen NV's Equity Buyback Plan announced on July 30, 2013.

January 30, 2014 at 02:30 am IST

From October 1, 2013 to December 31, 2013, the company has repurchased 845,338 shares, representing 0.36% for $18.97 million. With this, the company has completed the repurchase of 1,045,338 shares, representing 0.45% for $22.67 million under the buyback announced on July 30, 2013.

Latest news about Qiagen N.V.

Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50	27/06	MT
Qiagen Seeks M&A	21/06	CI
Transcript : Qiagen N.V. - Shareholder/Analyst Call	21/06
Sartorius on the downswing again - low since 2020 is approaching	19/06	DP
Invest Securities Raises Qiagen PT, Maintains Neutral Rating	19/06	MT
UBS Raises Qiagen Price Target to $46 From $44, Maintains Neutral Rating	18/06	MT
JPMorgan Raises Price Target on Qiagen to $54 From $52, Maintains Overweight Rating	18/06	MT
QIAGEN NV : Gets a Neutral rating from UBS	18/06	ZD
QIAGEN NV : Deutsche Bank reaffirms its Buy rating	18/06	ZD
QIAGEN NV : Berenberg remains its Buy rating	18/06	ZD
Frankfurt shares close: Dax recovers	17/06	DP
Transcript : Qiagen N.V. - Analyst/Investor Day	17/06
Dpa-AFX Overview: COMPANIES from 17.06.2024 - 15:15	17/06	DP
Qiagen Targets 7% Annual Sales Growth Through 2028	17/06	MT
Qiagen eyes sales growth of 7% per year until 2028	17/06	RE
QIAGEN Announces the Release of A New Version of Its Clinical Decision Support Software, QCI Interpret	14/06	CI
Qiagen Scraps NeuMoDx 96, 288 Molecular Systems; Raises 2024 Adjusted Earnings Outlook	07/06	MT
Qiagen to Discontinue NeuMoDx Integrated PCR Testing System	07/06	CI
Qiagen N.V. Reaffirms Earnings Guidance for the Second Quarter of 2024	07/06	CI
Qiagen N.V. Launches Digital PCR Assay Design Tool for QIAcuity, Expands Customization Capabilities of Its Research Platform GeneGlobe	06/06	CI
Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care	03/06	CI
Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test	31/05	MT
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test	31/05	MT
QIAGEN and Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications	31/05	CI
Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine	30/05	CI

Chart Qiagen N.V.

Duration

Period

More charts

Company Profile

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 07:02 pm IST

More Strategies

Ratings for Qiagen N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

40.58 USD

Average target price

50.37 USD

Spread / Average Target

+24.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QIAGEN N.V.	-9.37%	900.26Cr
MODERNA, INC.	+16.59%	4.44TCr
IQVIA HOLDINGS INC.	-10.62%	3.77TCr
LONZA GROUP AG	+40.49%	3.98TCr
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	3.15TCr
CELLTRION, INC.	-9.78%	2.7TCr
ICON PUBLIC LIMITED COMPANY	+12.34%	2.63TCr
UNITED THERAPEUTICS CORPORATION	+41.53%	1.38TCr
MEDPACE HOLDINGS, INC.	+31.49%	1.25TCr
BIO-TECHNE CORPORATION	-7.40%	1.13TCr

Other Biotechnology & Medical Research